The state government is calling for federal support for the project, which has been developed with US company Tiba BioTech.

Conservation is the name of the game in most ecological thinking - but in the eyes of some environmental philosophers, ...

Shareholders in Neuren Pharmaceuticals Ltd (ASX: NEU) are rejoicing after one of the company's drugs, which shows promise in treating a rare genetic disorder, received fast-track designation from the ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...

LONDON, Oct 15 (Reuters) - German biotech firm Tubulis said on Wednesday it had raised 308 million euros ($358 million) in its biggest financing round to date, contributing to a total of 495 million ...

Shares of Sana Biotechnology (NASDAQ:SANA) climbed ~24% in the morning hours on Wednesday, triggering several trading halts after Canadian hedge fund manager Eric Jackson said that he is long the ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — The German biotech Tubulis, which is designing a series of ...

A Bainbridge Island immunologist has been awarded the Nobel Prize in Physiology or Medicine for pioneering research that helped launch the field of peripheral immune tolerance, which is aiding ...

A rebound in global biotech deals is set to accelerate as big pharmaceutical companies seek new sources of revenue, according to the International Biotechnology Trust Plc. The pace of dealmaking has ...